[1]
J. F. Merola, “Bimekizumab 3-year Efficacy in High-Impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from Five Phase 3/3b Trials”, J of Skin, vol. 8, no. 1, p. s304, Jan. 2024.